1. Anti-infection NF-κB Autophagy Apoptosis
  2. Parasite NF-κB Autophagy Apoptosis
  3. Dihydroartemisinin

Dihydroartemisinin  (Synonyms: 双氢青蒿素; Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol)

目录号: HY-N0176 纯度: ≥98.0%
COA 产品使用指南

Dihydroartemisinin是一种有效的抗疟疾 (anti-malaria) 活性分子。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Dihydroartemisinin Chemical Structure

Dihydroartemisinin Chemical Structure

CAS No. : 71939-50-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥660
In-stock
5 mg ¥125
In-stock
10 mg ¥200
In-stock
50 mg ¥600
In-stock
100 mg ¥900
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Dihydroartemisinin:

    Dihydroartemisinin purchased from MCE. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr 14.  [Abstract]

    Dihydroartemisinin (DHA; 12.5, 25, 50 μM; 24 h) significantly reduces the viability of A549-GR cells in a dose-dependent manner.

    Dihydroartemisinin purchased from MCE. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr 14.  [Abstract]

    Dihydroartemisinin (DHA; 12.5, 25, 50 μM; 24 h) increases the expression of cleaved-Caspase 3, but decreases the expression of PARP and Bcl-2 in A549-GR cells.

    Dihydroartemisinin purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2023 Feb 16.

    Dihydroartemisinin (DHA; 50, 100 µM) remarkably inhibits single-cell colony formation of HSC3 cells and SAS cells in a dosage-dependent manner (Fig e and f).

    Dihydroartemisinin purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2018 Jun 27;501(3):636-642.  [Abstract]

    Immunoblot analysis of the expression levels of BCL-2 and BAX after treatment of HCT116 TP53-/- cells with 20 μM 5-FU and 1.25 μM DHA alone or in combination for 48 h. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control.
    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Dihydroartemisinin is a potent anti-malaria agent.

    IC50 & Target[1]

    RelA

     

    Plasmodium

     

    Autophagy

     

    体外研究
    (In Vitro)

    Dihydroartemisinin (DHA) 是一种抗疟药。Dihydroartemisinin 处理有效上调胞质 RelA/p65 蛋白水平并下调核 RelA/p65 蛋白水平,它阻断 RelA/p65 从胞质溶胶的核转运,而不是抑制 RelA/p65 蛋白合成。Dihydroartemisinin 在 RPMI 8226 细胞中诱导自噬。Dihydroartemisinin 抑制 RPMI 8226 细胞中的 NF-κB 活化。通过 EMSA 测定检查 NF-κB Dihydroartemisinin 结合活性[2]
    RPMI 8226 细胞暴露于不同浓度的 Dihydroartemisinin (10、20 和 40 μM) 12 小时,引入 TNF-α 作为 NF-κB 激活的阳性对照。与 TNF-α[1]相比,Dihydroartemisinin 以剂量依赖性方式抑制 NF-κB 活化。Dihydroartemisinin (DHA) 可增强光动力疗法 (PDT) 对食管癌细胞的抗肿瘤作用,用 Dihydroartemisinin (80 μM)、PDT (分别为 25 和 20 J/cm2) 或其组合处理 Eca109 和 Ec9706 细胞。Dihydroartemisinin 或 PDT 单次处理分别导致 Eca109 细胞活力降低 37±5% 或 34±6%,Ec9706 细胞活力降低 33±7% 或 34±6%。当 PDT 与 Dihydroartemisinin 联合使用时,细胞系的细胞活力分别降低了 59±6% 或 61±7%[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    Dihydroartemisinin (单次口服;200、300、400 或 600 mg/kg),在感染后第 6-8 天每天给药一次,可将总蠕虫负担减少 69.2%-90.6%,将雌性蠕虫负担减少 62.2% %-92.2%,取决于第一个实验中的剂量。在感染后第 34-36 天进行的类似处理可将总蠕虫负荷降低 73.9%-85.5%,将雌性蠕虫负荷降低 83.8%-95.3%[3]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    284.35

    Formula

    C15H24O5

    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    双氢青蒿素;二氢青蒿素

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性数据
    In Vitro: 

    DMSO 中的溶解度 : 25 mg/mL (87.92 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    Ethanol 中的溶解度 : 10 mg/mL (35.17 mM; 超声助溶)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 3.5168 mL 17.5840 mL 35.1679 mL
    5 mM 0.7034 mL 3.5168 mL 7.0336 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (7.31 mM); 悬浊液; 超声加热助溶

      此方案可获得 2.08 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (7.31 mM); 澄清溶液; 超声加热助溶

      此方案可获得 2.08 mg/mL的澄清溶液。

      1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.03%

    参考文献
    Kinase Assay
    [1]

    To determine NF-κB Dihydroartemisinin-binding activity, an electrophoretic mobility shift assay (EMSA) is performed. Nuclear extracts are prepared and incubated with 32P-end-labeled 45-mer double-stranded oligonucleotide (15 μg protein with 16 fmol DNA) from the HIV long terminal repeat, 5′-TTGTTACAAGGGACTTTCCGCTG GGGACTTTCCAGGGAGGCGTGG-3′ (boldface indicates NF-κB binding sites), for 30 min at 37 °C. The Dihydroartemisinin-protein complex formed is separated from free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5′-TTGTTACAA CTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3′, is used to examine binding specificity of NF-κB to the DNA. The binding specificity is also examined by competition with the unlabeled oligonucleotide. Preimmune serum (PIS) is included as a negative control. The dried gels are visualized with a Storm 820, and radioactive bands are quantified using Imagequant software[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [2]

    Eca109 (4×103 cells/well) and Ec9706 (5×103 cells/well) cells are grown in 96-well plates and cultured overnight to allow for cell attachment. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 μM), PDT (25 and 20 J/cm2, respectively) or their combination. After incubation for 24h, MTT (20 μL) is added to each well and incubated for 4 h at 37°C. Formazan crystals are dissolved in 150 μL of DMSO for 10 min with shaking. The absorbance is measured at 490 nm on a plate reader, and the experiment is repeated three times[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    Mice[3]
    Mice of the Kunming strain, each weighing 20-24 g, are used. In the first experiment, design to investigate the effect of multiple doses of Dihydroartemisinin on the schistosomula and adult worms of S. japonicum, mice are given three daily doses, of 200, 300, 400 or 600 mg Dihydroartemisinin/kg (in dose volumes of 25 mL/kg), on days 6-8 or 34-36 post-infection, respectively. An additional group of mice, infected but not given the drug, serve as a control.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 3.5168 mL 17.5840 mL 35.1679 mL 87.9198 mL
    5 mM 0.7034 mL 3.5168 mL 7.0336 mL 17.5840 mL
    10 mM 0.3517 mL 1.7584 mL 3.5168 mL 8.7920 mL
    15 mM 0.2345 mL 1.1723 mL 2.3445 mL 5.8613 mL
    20 mM 0.1758 mL 0.8792 mL 1.7584 mL 4.3960 mL
    25 mM 0.1407 mL 0.7034 mL 1.4067 mL 3.5168 mL
    30 mM 0.1172 mL 0.5861 mL 1.1723 mL 2.9307 mL
    DMSO 40 mM 0.0879 mL 0.4396 mL 0.8792 mL 2.1980 mL
    50 mM 0.0703 mL 0.3517 mL 0.7034 mL 1.7584 mL
    60 mM 0.0586 mL 0.2931 mL 0.5861 mL 1.4653 mL
    80 mM 0.0440 mL 0.2198 mL 0.4396 mL 1.0990 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Dihydroartemisinin
    目录号:
    HY-N0176
    需求量: